Key Points
- Oruka Therapeutics SVP Arjun Agarwal sold 10,000 shares at an average price of $106.66, generating $1.07 million. The Rule 10b5-1 transaction reduced his direct ownership by 39.51% to 15,312 shares.
- Oruka shares opened at $111.04, near their 52-week high of $111.37, and the company has a $7.35 billion market capitalization. Its latest quarterly loss of $0.55 per share was worse than analysts’ expected loss of $0.51.
- Analysts remain broadly bullish, with a “Moderate Buy” consensus and an average price target of $134.30; 56.44% of the stock is owned by institutional investors and hedge funds.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) SVP Arjun Agarwal sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the completion of the sale, the senior vice president directly owned 15,312 shares in the company, valued at $1,633,177.92. This represents a 39.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Arjun Agarwal also recently made the following trade(s):
- On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $84.63, for a total value of $846,215.37.
- On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The stock was sold at an average price of $80.95, for a total value of $128,467.65.
- On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.69, for a total transaction of $27,527.55.
- On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.72, for a total transaction of $659,481.48.
- On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The stock was sold at an average price of $59.07, for a total transaction of $607,830.30.
Oruka Therapeutics Stock Up 2.7%
Oruka Therapeutics stock opened at $111.04 on Friday. Oruka Therapeutics, Inc. has a 52-week low of $14.08 and a 52-week high of $111.37. The firm has a fifty day moving average of $87.52 and a 200-day moving average of $62.61. The firm has a market capitalization of $7.35 billion, a P/E ratio of -54.70 and a beta of -0.34.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). On average, research analysts expect that Oruka Therapeutics, Inc. will post -2.27 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on ORKA shares. Barclays upped their price target on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an "overweight" rating in a report on Monday, April 27th. UBS Group upped their target price on Oruka Therapeutics from $100.00 to $130.00 and gave the company a "buy" rating in a research report on Wednesday, July 1st. BTIG Research reiterated a "buy" rating and set a $151.00 target price on shares of Oruka Therapeutics in a research note on Tuesday. Wall Street Zen raised shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings upgraded shares of Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, July 15th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Oruka Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $134.30.
View Our Latest Stock Report on ORKA
Institutional Trading of Oruka Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in Oruka Therapeutics during the 2nd quarter valued at about $474,916,000. Viking Global Investors LP acquired a new stake in shares of Oruka Therapeutics during the third quarter worth $51,280,000. Paradigm Biocapital Advisors LP purchased a new position in Oruka Therapeutics in the 4th quarter worth about $51,840,000. Remedium Capital Partners LLC purchased a new position in shares of Oruka Therapeutics in the fourth quarter worth approximately $47,054,000. Finally, Jupiter Topco LLC acquired a new stake in shares of Oruka Therapeutics during the second quarter valued at approximately $130,968,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
